Caroline is a biopharmaceutical executive with over 20 years of experience successfully leading diverse, empowered and integrated teams. She has broad experience integrating science, business and the clinic to deliver differentiated value to patients. Most recently, she was Vice President, Head R&D Strategy and Planning at Bristol-Myers Squibb where she led portfolio strategy and operations. This included shaping BMS’s strategy and portfolio to deliver strong competitive positioning in immuno-oncology, immunoscience, fibrosis and cardiovascular, together with a new fit-for-purpose operating model. Her earlier career spanned leadership roles in commercial, market access, regulatory and drug development. An organic chemist by training, Caroline studied as an undergraduate and postgraduate at Imperial College, London.
Sangeeta Bhatia, MD, PhD
Sangeeta trained as a bioengineer and physician at Brown, MIT, Harvard, and MGH and currently heads the Cancer Nanomedicine Center at the Koch Institute at MIT. Her lab leverages miniaturization tools to impact human health, enabling new methods to model and regenerate tissue, diagnose and monitor disease, and deliver drugs and nucleic acid therapies. Bhatia is an elected member of the National Academy of Science, National Academy of Engineering, and National Academy of Invention, and the recipient of the Heinz Medal and the Lemelson-MIT prize. She currently serves as a Director at Vertex Pharmaceuticals and a Trustee at Brown University. Fun facts about Sangeeta: she likes yoga, all things coffee, good books, travel, being with friends and family and crafting with her daughters. Thanksgiving is her favorite holiday.
Gabe A Kwong, PhD
Co-Founder & Chief Scientific Officer
Gabe trained as a bioengineer at UC Berkeley, Caltech and MIT, and currently is a Principal Investigator at the Lab for Synthetic Immunity at Georgia Tech and Emory School of Medicine. His research merges engineering approaches with discoveries in immunology to advance human health. He and his team have developed innovative technologies that shape broad applications in biomedical diagnostics and cell-based therapies, and impact frontier challenges in cancer, transplant medicine and infectious diseases. When he is not in the lab or classroom, Gabe can be found hiking, playing guitar, or at the gym training for his favorite show: American Ninja Warrior.
Eric K Huang, PhD
Chief Development Officer
Eric trained as a bioengineer at Brown and Rutgers. Prior to Glympse, Eric held leadership roles at Acusphere and Epirus Biopharmaceuticals in product development, business development, technical operations, and program management. At Glympse, Eric leads all development activities including overseeing day-to-day operations. When he’s not in charge of all things Glympse, Eric loves to ski and tend to his cichlid fish tank. He also likes to let his kids take over just to see what they’ll do...and he’s frequently impressed by what they come up with.
Chief Business Officer
Roopom studied biology and economics at MIT and Harvard, and at Glympse is focused on strategy, financing, partnering, and intellectual property. Most recently, Roopom was the President & CEO at RainDance Technologies (acquired by BioRad Labs). Previously, Roopom worked at Leerink Swann, McKinsey, and Goldman Sachs to complete 70+ private/public financings and M&A transactions. In his former science life, Roopom worked in cancer genomics at the Dana Farber, Whitehead Institute and MGH. Roopom is an avid tennis player and channels his inner adrenaline junkie into mountain biking as well as nature photography.